Successful completion of two public offerings in the past 12 months has provided over $80 million in new cash for our clinical programs.
Our efforts to advance Blisibimod for patients with severe, autoimmune disease remain our top priority and the continual support of our shareholders in 2012 and 2013 has provided the foundation. Successful completion of two public offerings in the past 12 months has provided over $80 million in new cash for our clinical programs. Our commitment remains to utilize this capital in the most efficient and cost effective manner as we advance Blisibimod in two global clinical studies. We’ve elected to retain all global rights to Blisibimod as we accelerate through these next stages of development. As a result, other than small royalties and milestones to Amgen, we managed to keep substantially all of Blisibimod’s potential future value.
In closing, all of us at Anthera remain proud and humbled by the support of our collaborators, doctors, nurses, patients, and investors who, in spite of the challenges faced by drug development, have placed their trust in our efforts to improve the lives of people with autoimmune diseases. We are determined to fundamentally shift and improve the future of these patients by providing revolutionary treatment options like Blisibimod. By doing that well, we will create extraordinary value for the patients we serve and for all of our Stakeholders.
Paul Truex took an 8 dollar ipo and turned it into a 53 cent stock in about 4 years. He has made millions of dollars in stock and salary. And now, he is proud and humbled to continue this charade despite overwhelming evidence that B-mod has no economic value whatsoever.